欧盟国家药品价格管理简介及其评价  

Review and Brief Introduction to Pharmaceutical Pricing Management in EU

作　　者：赵伟[1] 童冠圣[1] 

机构地区：[1]首都医科大学附属北京世纪坛医院物价科,北京100038

出　　处：《中国卫生经济》2013年第3期70-72,共3页Chinese Health Economics

基　　金：国家自然科学基金项目(71173003);国家自然科学基金项目(81172201)

摘　　要：在欧盟国家,药品市场是受到最严厉管制的市场之一。通过价格管制、疗效-成本定价、利润控制、参考定价、国际参考定价、费用返还、费用分担、鼓励合理用药、非专利药政策等干预措施,政府力图实现控制药费支出,同时保障药品供应和公平性、保证药物质量和鼓励药品企业创新。欧盟国家在药品价格管理方面的多样性为我国制定相关政策提供了有益的参考。In most Europe Union （EU） countries, the pharmaceutical market is the most heavily regulatedone. Through different approaches of pharmaceutical pricing management, such as price control, cost-effectiveness pricing, profit control, reference pricing, international reference pricing, cost-sharing, payback, incentives for good prescribing practice and generics policy, authorities of EU countries try to control pharmaceutical expenditure, to secure, the availability, equality and safety to patients, and to encourage industry innovation. A variety of pharmaceutical pricing management in different EU countries can provide a useful reference to draw up policy in China.

关 键 词：药品 价格管理 欧盟 

分 类 号：R95[医药卫生—药学] F714.1[经济管理—产业经济]